Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
MB-CART 19.1 by Miltenyi Biomedicine for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
MB-CART 19.1 is under clinical development by Miltenyi Biomedicine and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL)....
MB-CART 19.1 by Miltenyi Biomedicine for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
MB-CART 19.1 is under clinical development by Miltenyi Biomedicine and currently in Phase II for Relapsed Chronic Lymphocytic Leukemia (CLL)....
MB-CART 19.1 by Miltenyi Biomedicine for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
MB-CART 19.1 is under clinical development by Miltenyi Biomedicine and currently in Phase II for B-Cell Non-Hodgkin Lymphoma. According to...
MB-CART 19.1 by Miltenyi Biomedicine for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
MB-CART 19.1 is under clinical development by Miltenyi Biomedicine and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute...